ASCO 2022 Resources

Research Services Portfolio – Transformative Insights from Discovery to Clinic

This comprehensive brochure provides an overview of our services offering.

TrueTarget™ Brochure – Novel Drug Target Identification and Validation

Learn more about Biognosys’ proprietary TrueTarget™ platform in our latest brochure. This resource elaborates on how TrueTarget™ identifies the most promising and actionable drug targets to support your research.

White Paper – How To Accelerate And De-Risk Drug Development In Oncology

In this white paper, you can learn about the key reasons why oncology drug development fails and how Biognosys’ proteomics platforms and applications can support your oncology research pipeline by:

• Understanding the right biology
• Hitting the right target
• Developing the right biomarkers

White Paper – Accelerating Biomarker Discovery With Large-Scale Plasma Proteomics

Our White Paper explains how advances in mass spectrometry can now unlock the potential of the plasma proteome, uncovering actionable insights that are essential for biomarker discovery and targeted drug development.

Case Study – Biomarker Candidates for Tumors Identified from Deep‐profiled Plasma Stem Predominantly from the Low Abundant Area

The case study provides you with an overview of the key features and benefits of our next-generation Plasma Biomarker Discovery solution. In addition, the case study elaborates on the results from our latest pan-cancer proteomics study.

Publication – Dynamic 3D Proteomes Reveal Protein Functional Alterations at High Resolution in Situ

Cappelletti V, Hauser T, Piazza I, Pepelnjak M, Malinovska L, Fuhrer T, Li Y, Dörig C, Boersema P, Gillet L, Grossbach J, Dugourd A, Saez-Rodriguez J, Beyer A, Zamboni N, Caflisch A, Souza N, Picotti P. Cell

In this study, an ETH Zurich team led by Biognosys’ scientific advisor and inventor of the LiP-MS technology, Paola Picotti, has spearheaded the exploration of protein functional states in a proteome-wide manner. The team investigated the role of protein structural alterations as a first-line cellular response. Integrating peptide-level LiP-MS data with orthogonal information such as phosphorylation enabled the linking of protein structural changes to functional implications. This work demonstrates the potential of integrating structural and abundance-based proteomics to achieve deeper insights into biological processes.

Publication – Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods

J. Adam Hendricks, Nigel Beaton*, Alexey Chernobrovkin, Eric Miele, Ghaith M. Hamza, Piero Ricchiuto, Ronald C. Tomlinson, Tomas Friman, Cassandra Borenstain, Bernard Barlaam, Sudhir Hande, Michelle L. Lamb, Chris De Savi, Rick Davies, Martin Main, Joakim Hellner, Kristina Beeler, Yuehan Feng, Roland Bruderer, Lukas Reiter, Daniel Martinez Molina*, and M. Paola Castaldi*. American Chemical Society’s Chemical Biology Journal.

The publication shows how orthogonal proteomics approaches can be applied to quantitatively profile the selectivity of a new compound. Biognosys’ proprietary Limited Proteolysis Mass Spectrometry (LiP-MS) technology was used to screen the entire proteome and identify potential targets via structural alterations. In addition to target identification, by exploiting the technology’s peptide-level resolution – a unique feature of the approach – we could also identify the putative binding site of the CDK inhibitor. In this way, LiP-MS enabled the target identification, binding affinity estimation, and binding site localization of the analyzed compound.